Clinical Trials

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects with Multiple Myeloma (KarMMa-2)


Study ID
Celgene bb2121 MM-002

NCT Number
NCT03601078 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0619

Principle Investigator
Dr. David Siegel

Phase
II

Sponsor
Celgene


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now